TRANEXAMIC ACID INJECTION SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

TRANEXAMIC ACID

थमां उपलब्ध:

AURO PHARMA INC

ए.टी.सी कोड:

B02AA02

INN (इंटरनेशनल नाम):

TRANEXAMIC ACID

डोज़:

100MG

फार्मास्यूटिकल फॉर्म:

SOLUTION

रचना:

TRANEXAMIC ACID 100MG

प्रशासन का मार्ग:

INTRAVENOUS

पैकेज में यूनिट:

100

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

HEMOSTATICS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0114760002; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2019-01-18

उत्पाद विशेषताएं

                                Page 1 of 26
_PRODUCT MONOGRAPH _
_TRANEXAMIC ACID INJECTION _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TRANEXAMIC ACID INJECTION
Tranexamic acid injection
Solution, 100 mg / mL, Intravenous
House Standard
Antifibrinolytic agent
AURO PHARMA INC.
Date of Revision:
3700 Steeles Avenue West, Suite # 402
January 15, 2019
Woodbridge, Ontario, L4L 8K8,
Canada.
Date of Initial Authorization:
July 06, 2017
Date of Revision:
January 03, 2023
Submission Control Number: 266686
Page 2 of 26
_PRODUCT MONOGRAPH _
_TRANEXAMIC ACID INJECTION _
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
01/2023
4 DOSAGE AND ADMINISTRATION, 4.4 Administration
01/2023
7 WARNINGS AND PRECAUTIONS
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
1 INDICATIONS
......................................................................................................................
4
1.1 Pediatrics
..............................................................................................................
4
1.2 Geriatrics
..............................................................................................................
4
2 CONTRAINDICATIONS
.........................................................................................................
4
4 DOSAGE AND
ADMINISTRATION.........................................................................................
4
4.1 Dosing Considerations
...........................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
........................................................ 5
4.3 Reconstitution
......................................................................................................
5
4.4 Administration

                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 03-01-2023

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें